Also, work led by the Nash group in 2014 found that the use of AAV2 to deliver soluble FKN reduced α-synuclein-mediated neurodegeneration in the MTPT model of PD in rats (Nash et al., 2015). Here, CX3CL1 is linked to Parkinson disease.